

**Pharmacy and Therapeutics Committee & Drug Utilization Review Board**  
**Meeting by Zoom Webinar**  
**Wednesday, December 15, 2021 9 a.m. to 4 p.m.**

Agenda		
Time	Topic	Presenter
9 a.m.	<b>Welcome &amp; Introductions</b>  <b>Pharmacy &amp; Therapeutics (P&amp;T) Committee Convenes (Reviews drug classes for the WA PDL)</b>  <b>Committee vote on new chair and vice chair</b>	Ginni Buccola, Committee Chair
9:10 a.m.	Antidepressants surveillance report <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Shannon Robalino, DERP
9:35 a.m.	CGRP surveillance report <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Curtis Harrod, DERP
10 a.m.	<b>P&amp;T Committee Adjourns</b>  <b>Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)</b>	Ginni Buccola, Committee Chair
10 a.m.	Apple Health Policy: Spinraza <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Marissa Tabile, HCA
10:20 a.m.	Apple Health Policy: Evrysdi <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Luke Dearden, HCA
10:40 a.m.	<b>DUR Board Adjourns</b>  <b>Break (10 min)</b>	Ginni Buccola, Committee Chair All
10:50 a.m.	<b>P&amp;T Committee Convenes</b>	Ginni Buccola, Committee Chair
10:50 a.m.	ADHD full report <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Shannon Robalino & Andrea Vintro, DERP
12:05 p.m.	<b>P&amp;T Committee Adjourns</b>  <b>Break (30 min)</b>	All
12:35 p.m.	<b>DUR Board Convenes</b>	Ginni Buccola, Committee Chair
12:35 p.m.	Apple Health Policy: Cabenuva <ul style="list-style-type: none"> <li>• Stakeholder input*</li> </ul>	Marissa Tabile, HCA

*\* Stakeholders will be allowed 3 minutes for comments.*

*Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> <li>• Motion</li> </ul>	
12:55 p.m.	<b>Apple Health drug class reviews:</b> Analgesics : Opioid Agonists - Long Acting <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
1:10 p.m.	Antiemetics / Antivertigo Agents : <ul style="list-style-type: none"> <li>• 5-HT3 Receptor Antagonists</li> <li>• Substance P/Neurokinin 1 (NK1) Receptor Antagonists</li> <li>• Substance P/Neurokinin 1 Receptor Antagonist Combinations <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
1:15 p.m.	Antihypertensives : <ul style="list-style-type: none"> <li>• Direct Renin Inhibitor Combinations</li> <li>• Direct Renin Inhibitor</li> <li>• Nephilysin Inhib (ARNI)-Angiotensin II Recept Antag Combinations <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
1:30 p.m.	Antivirals : Hepatitis C Agents <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
2 p.m.	<b>Break (10 min)</b>	All
2:10 p.m.	Antivirals : <ul style="list-style-type: none"> <li>• HIV</li> <li>• HIV Combinations <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
3 p.m.	HIV Utilization Presentation	Donna Sullivan, HCA
3:30 p.m.	Endocrine and Metabolic Agents : <ul style="list-style-type: none"> <li>• Androgens - Testosterone</li> <li>• Bone Density Regulators - Sclerostin Inhibitors <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
3:35 p.m.	Migraine Agents : <ul style="list-style-type: none"> <li>• Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists</li> <li>• Selective Serotonin Agonists 5-HT(1) <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
3:50 p.m.	Pulmonary Hypertension Agents : <ul style="list-style-type: none"> <li>• Endothelin Receptor Antagonists</li> <li>• Prostacyclin Receptor Agonists</li> <li>• Prostaglandin Vasodilators</li> <li>• SGC Stimulator</li> <li>• Phosphodiesterase Inhibitors (PDEI) <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan

*\* Stakeholders will be allowed 3 minutes for comments.*

*Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

4 p.m.	<b>DUR Board Adjourns</b>	Ginni Buccola, Committee Chair
--------	---------------------------	-----------------------------------

*For all Apple Health (Medicaid) questions, please email [AppleHealthPolicy@hca.wa.gov](mailto:AppleHealthPolicy@hca.wa.gov)*



*\* Stakeholders will be allowed 3 minutes for comments.  
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions  
please call Leta Evaskus at 206-521-2029.